InVision Medical Technology

What InVision Medical Technology does

InVision Medical Technology is a Los Angeles-based, Delaware-incorporated medical AI company founded in 2022 that develops FDA-cleared deep-learning software for the interpretation of echocardiograms (cardiac ultrasound). The company builds on a decade of academic research originating at Stanford University and Cedars-Sinai Medical Center, led by co-founders Dr. David Ouyang, MD (a practicing cardiologist at Kaiser Permanente Northern California) and Dr. Bryan He, PhD. InVision's product platform comprises two FDA 510(k)-cleared algorithms — Precision LVEF (automated ejection-fraction measurement, cleared May 2024) and Precision Cardiac Amyloid (AI detection of cardiac amyloidosis, cleared May 2025) — along with three development-stage modules: Precision Cirrhosis (opportunistic liver-disease screening, FDA Breakthrough Device Designation November 2025), Precision Reporting (structured reporting powered by the EchoPrime and EchoNet-Measurements foundation models published in Nature and JACC), and Automatic DICOM Deidentification (HIPAA/SOC 2/DICOM Part 15 compliant). The company also offers an AI-assisted Echo Core Lab service for clinical-trial sponsors.

The underlying technology consists of in-house deep-learning models trained on what the company describes as the largest echocardiographic video dataset among FDA-cleared echo AI products, including a 12-million video-report-pair foundation model (EchoPrime), 877,983 sonographer annotations across 155,000+ studies (EchoNet-Measurements), and a 1.6-million-video liver-screening pipeline (EchoNet-Liver). Input is standard DICOM echocardiographic video; output includes ejection fraction, 18 automated B-mode and Doppler parameters, valve-disease classifications, structured report drafts, and risk scores. The software is delivered as DICOM-native post-processing that integrates with existing PACS, Epic EHR, and structured-reporting platforms without new hardware.

InVision generates revenue through enterprise B2B software licensing of its FDA-cleared AI products to health-system cardiovascular service lines, supported by the CPT Category III code 0932T (effective January 2025) that provides reimbursement for AI-assisted echocardiographic evaluation in heart failure, plus professional-service revenue from AI-assisted Echo Core Lab work for pharmaceutical and CRO clinical-trial sponsors. Distribution is direct enterprise field sales plus channel partnerships (HeartLab, Dandelion Health) and a strategic co-development alliance with Alexion, AstraZeneca Rare Disease. Pricing is quote-based enterprise and not publicly disclosed; the company is privately held and Y Combinator-backed.

Name

InVision Medical Technology

Legal name

InVision Medical Technology Corporation

Website

https://invisionmedtech.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

InVision Medical Technology builds FDA-cleared deep-learning software for echocardiogram interpretation — including automated ejection fraction and cardiac amyloidosis detection — sold to US health-system cardiovascular service lines and pharmaceutical clinical-trial sponsors, with a dedicated CPT reimbursement code.

Ownership category

akta.pro rank

Product category

Cardiac Medical Imaging AI Software

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391), Medical and Diagnostic Laboratories (62151)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ)

akta.pro secondary industries

AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG), Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity) (HLACABAM), Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI), Medical Imaging AI (HDAAAEAH)

Keywords

• AI echocardiography analysis
• Cardiac imaging software
• FDA-cleared SaMD
• Medical AI diagnostics
• Clinical trial core lab

Headquarters

HQ city

Los Angeles

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain, Others

Revenue model

1. FDA-cleared AI Software (Precision LVEF, Precision Cardiac Amyloid): B2B enterprise software licensing to health systems. CPT Category III code 0932T (effective January 1, 2025) provides reimbursement path for AI-assisted echocardiographic evaluation for patients with heart failure symptoms.
2. Echo Core Lab Services: AI-assisted echocardiography core lab services for clinical trials. Combines AI first-pass measurement with expert sonographer and cardiologist adjudication. Targets pharmaceutical companies and clinical research organizations.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

InVision Medical Technology develops and commercializes FDA-cleared AI software that analyzes echocardiogram (cardiac ultrasound) videos to automate measurements, detect under-diagnosed diseases such as cardiac amyloidosis and cirrhosis, and generate structured reports. The platform is sold as enterprise Software-as-a-Medical-Device to hospital cardiovascular service lines and is complemented by an AI-assisted echo core lab service for pharmaceutical and CRO clinical trial sponsors.

Product overview

InVision Medical Technology offers a platform-plus-cleared-algorithms architecture built on a decade of Stanford and Cedars-Sinai research. The platform is anchored by two FDA 510(k)-cleared algorithms — Precision LVEF (automated ejection fraction, the only AI-echo product with a blinded RCT, Nature 2023) and Precision Cardiac Amyloid (cardiac amyloidosis detection, developed with Alexion/AstraZeneca Rare Disease, JAMA Cardiology 2022) — both reimbursable under CPT code 0932T effective January 2025. Adjacent modules include Precision Reporting (automated structured reports from EchoPrime and EchoNet-Measurements foundation models), Precision Cirrhosis (opportunistic liver disease screening, NEJM AI 2025, FDA Breakthrough Device Designation), and Automatic DICOM Deidentification (DICOM Part 15 + HIPAA compliant). An Echo Core Lab service wraps the AI into a human-in-the-loop read service for clinical trials. A valve disease pipeline (mitral, tricuspid, aortic) is in active development, with mitral and tricuspid peer-reviewed in Circulation 2024 and JAMA Cardiology 2025.

Differentiator

Problem solved

Functional benefit

Products and services

• Precision LVEF FDA 510(k)-cleared AI software for automated evaluation of left ventricular ejection fraction (LVEF) and chamber metrics from standard echocardiographic DICOM studies. The only AI-echo product with blinded, randomized prospective clinical trial evidence (Nature 2023), demonstrating time savings and improved measurement consistency vs. sonographer reads. Sold to health system echo labs.
• Precision Cardiac Amyloid FDA 510(k)-cleared AI software for detection of cardiac amyloidosis from apical-4-chamber and parasternal-long-axis echocardiographic views. Integrates multi-view information; previously received Breakthrough Device Designation and FDA TAP enrollment. Reimbursed under CPT code 0932T (effective Jan 1, 2025). Co-developed with Alexion, AstraZeneca Rare Disease.
• Precision Cirrhosis AI for opportunistic detection of cirrhosis and steatotic liver disease from the subcostal view captured during routine echocardiography. Built on EchoNet-Liver (NEJM AI 2025), developed from 1.6M echocardiogram videos and validated against paired abdominal ultrasound and MRI. FDA Breakthrough Device Designation granted November 2025; AHA-funded prospective multi-center trial underway.
• Precision Reporting Automated structured echocardiographic reporting powered by two foundation models: EchoPrime (Nature 2025, 12M+ video-report pairs) and EchoNet-Measurements (JACC 2025, 877,983 sonographer annotations). Delivers holistic multi-view interpretation and automates 18 standard B-mode and Doppler parameters with R² 0.97–0.99 vs. expert sonographers.
• Automatic DICOM Deidentification Automated compliance utility removing both burnt-in pixel-level PHI and structured DICOM metadata from echocardiographic studies. Compliant with DICOM Part 15, HIPAA, and SOC 2 Type 2. Fully automated pipeline requiring no manual review for routine studies.
• Echo Core Lab AI-assisted echocardiography core lab service pairing automated first-pass measurement (EchoNet-Measurements + EchoPrime) with expert sonographer adjudication and cardiologist finalization. Designed for clinical trial endpoints; delivers locked, versioned, audit-ready reports with 48–72 hour turnaround for routine clinical reads. Targets pharmaceutical sponsors and CROs running cardiovascular trials.

Quantifiable outcome

• AI studies substantially changed by cardiologist at 16.8% vs 27.2% for sonographer studies (Nature 2023 RCT)
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability8 records

Feature8 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Dandelion HealthcoreStrategic or Co-development Partner · 30 April 2026Partnership to bring InVision's echocardiography AI onto Dandelion's Clinical AI Marketplace. InVision's AI analyzes raw imaging data from echocardiograms and generates up to 30x more cardiac measurements per patient, layered onto Dandelion's decade of longitudinal real-world patient records. Powers research across heart failure, ASCVD, cardiomyopathies, cardio-oncology, and cardiometabolic landscape.
• Alexion, AstraZeneca Rare DiseasecoreStrategic or Co-development Partner · 16 November 2023Multi-year collaboration to co-develop AI algorithm for routine echocardiographic analysis to accelerate early detection of cardiac amyloidosis. Alexion provided development support and clinical footprint in rare disease. InVision's Precision Cardiac Amyloid was developed with Alexion support and subsequently received FDA 510(k) clearance in May 2025.
• HeartLabminorChannel Partner/ Reseller/ DistributorLive deployments of InVision's echo AI products through HeartLab partnership.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Caption Health (GE HealthCare): The closest direct competitor in AI echocardiography, originally focused on AI-guided cardiac ultrasound acquisition and now part of GE HealthCare. Caption Health competes head-to-head with InVision in automating echo interpretation and benefits from GE HealthCare's installed PACS/ultrasound base.
• Ultromics: UK-based AI echocardiography company with FDA-cleared products (e.g., EchoNous, EchoCLIP-style functionality) for cardiac amyloidosis and HFpEF detection. Ultromics is the most direct peer to InVision's Precision Cardiac Amyloid and EchoNet measurement products.

Broad incumbents

• Philips (Cardiology AI): Major imaging incumbent offering AI features across its ultrasound and cardiology portfolio, including automated cardiac quantification. Competes with InVision primarily through bundling into enterprise ultrasound contracts and existing PACS/EHR integrations.
• GE HealthCare: Global imaging incumbent owning Caption Health and a large installed base of ultrasound, PACS, and EHR-integrated cardiology tools. Competes with InVision on price/bundling rather than head-to-head on echo AI evidence, but represents the dominant distribution channel threat.
• Siemens Healthineers: Imaging and diagnostics incumbent with AI-enabled cardiac ultrasound offerings (e.g., eSie Left Heart). Comparable to InVision as an enterprise echo AI alternative bundled with hospital-wide imaging contracts and integrated with major PACS/EHR systems.

Emerging players

• HeartLab: AI-powered echocardiography reporting and analysis platform based in New Zealand. HeartLab is both a deployment partner of InVision and a partial competitor in the echo AI space, particularly in automated reporting and measurement workflows.
• Eko Health: Digital stethoscope and cardiac AI company with FDA-cleared algorithms for murmur and AFib detection. While focused on primary-care cardiac screening rather than echo, Eko represents an adjacent AI-cardiology competitor pursuing similar clinical-evidence-led enterprise GTM.
• Viz.ai: AI-powered clinical workflow company initially focused on stroke imaging but expanding into cardiology (e.g., cardiac echo AI and HF detection). Comparable to InVision as a specialty clinical AI vendor with FDA-cleared imaging algorithms and health-system enterprise sales motion.
• Circle CVI: AI cardiac MRI and CT analysis platform with FDA-cleared products for cardiovascular imaging quantification. Comparable to InVision as an enterprise cardiac AI vendor targeting the same cardiovascular service line buyers and addressing adjacent modalities (CMR/CT vs. echo).

Others

• Tempus AI: AI-driven precision medicine company with a large multimodal clinical data platform and imaging AI capabilities. Comparable to InVision through its Dandelion Health marketplace partnership but operates at a much broader oncology/cardiology scale as a data and AI infrastructure provider.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/InVision_AI

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InVision Medical Technology